Can AI help humans understand animals and reconnect with nature? A nonprofit research lab thinks so
US must not become complacent to a growing terrorism threat, a Counterterrorism Center official says
Your job may be affecting the quality of your sleep, new study finds
Israel supplied Iran with centrifuge platforms containing explosives, top official acknowledges
Look of the Week: Timothée Chalamet adopts London’s most stylish accessory
Republican bill seeks to curtail US FTC's merger-busting powers
Texas online porn age-verification law goes to US Supreme Court
Overtourism was the buzzword of 2024. This summer looks to be just as crowded and chaotic
(Reuters) - Agilent Technologies said on Monday it will acquire contract drug manufacturer Biovectra for $925 million to expand its portfolio of services offered to biotech companies and medical researchers.
Canada-based Biovectra offers fill-and-finish services for drug manufacturers. It also operates a business that makes active ingredients for complex drugs and has expertise in fast-growing segments such as the GLP-1 weight loss drugs, Agilent said.
Agilent has been struggling with soft demand for medical tools and equipment used in clinical studies as its biotech clients face a funding crunch.
The company said it will fund the transaction using a mix of cash on hand and debt financing, adding that Biovectra will become a part of its diagnostics and genomics unit.
The deal will have a dilutive impact of 5 cents on Agilent's profit, a year after the close of the Biovectra transaction.
Biovectra, previously a unit of Mallinckrodt, was acquired by private equity firm H.I.G. Capital in 2019 for $250 million.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta)
